

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU BIOPHARMA CO., LTD.

樂普生物科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2157)

**POLL RESULTS OF THE 2021 ANNUAL GENERAL MEETING
HELD ON JUNE 21, 2022**

The Board is pleased to announce that all the resolutions proposed as set out in the Notice of AGM were duly passed by the Shareholders by way of poll at the AGM.

References are made to the notice (the “**Notice of the AGM**”) and the circular (the “**Circular**”) of the 2021 annual general meeting (the “**AGM**”) of Lepu Biopharma Co., Ltd. (the “**Company**”) both dated May 30, 2022. Capitalised terms used herein shall have the same meanings as those defined in the Circular unless the context requires otherwise.

POLL RESULTS OF THE AGM

The AGM was chaired by Dr. Pu Zhongjie, the chairman of the Board and an executive Director, and was successfully held at Conference Room, Building 7, No. 37 Chaoqian Road, Changping District, Beijing, PRC on Tuesday, June 21, 2022 at 10:00 a.m.. The AGM was convened in accordance with the requirements of the relevant laws and regulations of the PRC and the Articles of Association, and the poll results of the AGM are lawful and valid.

The Board is pleased to announce that all the resolutions proposed at the AGM as set out in the Notice of AGM were duly passed by the Shareholders by way of poll at the AGM.

The poll results in respect of all the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS		NO. OF SHARES VOTED (%)	
		FOR	AGAINST
1.	To consider and approve the resolution on the report of the Board of Directors of the Company for the year 2021.	1,210,648,997 (100%)	0 (0%)
2.	To consider and approve the resolution on the report of the Board of Supervisors of the Company for the year 2021.	1,210,648,997 (100%)	0 (0%)
3.	To consider and approve the resolution on the annual report of the Group for the year 2021.	1,210,648,997 (100%)	0 (0%)
4.	To consider and approve the resolution on the financial accounts report of the Group for the year 2021.	1,210,648,997 (100%)	0 (0%)
5.	To consider and approve the resolution on the financial budget of the Group for the year 2022.	1,210,648,997 (100%)	0 (0%)
6.	To consider and approve the resolution on the annual profit distribution plan of the Company for the year 2021.	1,210,648,997 (100%)	0 (0%)
7.	To consider and approve the re-appointment of PricewaterhouseCoopers as the auditor of the Company for 2022, for a term commencing from the date of approval at the AGM until the conclusion of the 2022 annual general meeting of the Company, and authorize the Board to determine the specific matters, including but not limited to their remunerations, in relation to such re-appointment.	1,210,648,997 (100%)	0 (0%)
SPECIAL RESOLUTION		NO. OF SHARES VOTED (%)	
		FOR	AGAINST
8.	To consider and approve the resolution on the grant of a general mandate to the Board to issue shares.	1,210,648,997 (100%)	0 (0%)

As more than one-half of the votes were cast in favour of each of the resolutions numbered 1 to 7 above, these resolutions were duly passed as ordinary resolutions of the Company.

As more than two-thirds of the votes were cast in favour of the resolution numbered 8 above, this resolution was duly passed as a special resolution of the Company.

Notes:

1. As at the date of the AGM, the total number of issued ordinary Shares was 1,659,444,838 Shares (including 1,605,176,474 H Shares and 54,268,364 Domestic Shares), which represented the total number of Shares entitling the Shareholders to attend and vote on the proposed resolutions at the AGM.
2. There were no Shareholders, who, pursuant to Rule 13.40 of the Listing Rules, were required to abstain from voting in favour of any of the proposed resolutions at the AGM, nor were there any Shareholders who were required under the Listing Rules to abstain from voting.
3. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.
4. The total number of issued Shares held by the Shareholders or their proxies who have attended the AGM and are entitled to vote is 1,210,648,997 Shares, representing approximately 72.96% of the total number of issued Shares as at the date of the AGM.
5. The Company's H shares registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.
6. All Directors attended the AGM in person or via electronic means.

By order of the Board
Lepu Biopharma Co., Ltd.
Dr. Pu Zhongjie
Chairman of the Board and Executive Director

Shanghai, the PRC, June 21, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Pu Zhongjie as chairman and executive director, Dr. Sui Ziye as executive director and chief executive officer, Dr. Hu Chaohong as executive director and co-chief executive officer, Ms. Pu Jue, Mr. Yang Hongbing and Mr. Lin Xianghong as non-executive directors, and Mr. Zhou Demin, Mr. Yang Haifeng and Mr. Fengmao Hua as independent non-executive directors.